Elevation Oncology Inc Share Price

NASDAQ: ELEV

$0.37

(-1.29%) ▲

as on July 23, 2025 at 1:29 am IST

$₹

The stock has been delisted from the stock exchange on 22 Jul 2025

Elevation Oncology Inc Stock Performance

as on July 23, 2025 at 1:29 am IST

$0.37
Day's Price Range
$0.37
$0.37
52 Week's Low
52 Week's High
$0.22
52-Week Price Range
$0.98
$0.37
40.27%
Downside
164.86%
Upside

Elevation Oncology Inc share price movements today

Previous Close: $0.37
Open: $0.37
Volume: 150.0
Day's Low - High: $0.37 - $0.37
52 Week Low - High: $0.22 - $0.98

Elevation Oncology Inc Historical Returns

1 Month Return: 0 %
3 Month Return: 0 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

Elevation Oncology Inc Stock Fundamentals & Key Indicators

Check Elevation Oncology Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

EPS (TTM)

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

P/B Ratio

PEG Ratio

EBITDA

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

0.00%

Elevation Oncology Inc stock Key Stats

Compare market cap, revenue, PE, and other key metrics of Elevation Oncology Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Elevation Oncology Inc	BUY	$-	NA	NA	0.00%

Analyst Recommendation on Elevation Oncology Inc Stock

Based on 11 analysts

BUY

90.91%

Buy

9.09%

Hold

0.00%

Sell

Based on 11 analysts, 90.91% of analysts recommend a 'BUY' rating for Elevation Oncology Inc. Average target price of $0.39

Elevation Oncology Inc Share Price Target

Get share price movements and forecasts by analysts on Elevation Oncology Inc.

What analysts predicted

5.13%UPSIDE

Target Price

$0.39

Current Price

$0.37

Analyzed by

11 Analysts

Target

$0.39

Elevation Oncology Inc target price $0.39, a slight upside of 5.13% compared to current price of $0.37. According to 11 analysts rating.

Elevation Oncology Inc Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Total Revenue	-	-	-	-	0	-	-	-	-	-
Gross Profit	0	0	0	0	0	0	0	0	-	-
Operating Income	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-	-	-	-
Income Before Tax	-	-	-	-	-	-	-	-	-	-
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-19	-17	-10	-10	-7	-10	-10	-12	-10	-14
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	-13618.97%	0.00%	0.00%	0.00%	0.00%	0.00%

Elevation Oncology Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	-	-	-	-	-
Gross Profit	0	0	0	0	-
Operating Income	-	-	-	-	-
EBITDA	-	-	-	-	-
Interest Expense	-	-	-	-	-
Depreciation	-	-	-	-	-
Income Before Tax	-	-	-	-	-
Income Tax Expense	-	-	-	-	-
Net Income	-17	-32	-95	-45	-44
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%

Global Institutional Holdings in Elevation Oncology Inc

Funds	Holdings
BML Capital Management LLC	9.94%
TANG CAPITAL MANAGEMENT LLC	8.03%
BlackRock Inc	5.36%
Aisling Capital Management LP	4.78%
Vanguard Group Inc	4.36%

See all

About Elevation Oncology Inc

Elevation Oncology, Inc. is an oncology company. The Company is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021, is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. EO-3021 consists of a fully human immunoglobulin G1 (IgG1) mAb that targets Claudin 18.2 and is site-specifically conjugated to the monomethyl auristatin E (MMAE) payload via a cleavable linker with a drug-to-antibody ratio (DAR) of 2. EO-3021 is designed to bind to Claudin 18.2 on the cell surface and is internalized, upon which the linker is cleaved in the lysosome to release the MMAE payload, a potent anti-mitotic agent. Its second program is an ADC designed to target HER3, which is overexpressed across solid tumors. EO-1022 is an ADC containing seribantumab.

Organisation	Elevation Oncology Inc
E-voting on shares	Click here to vote

FAQs

What is Elevation Oncology Inc share price today?

Elevation Oncology Inc share price today is $0.37 as on July 23, 2025 at 1:29 am IST. Elevation Oncology Inc share today touched a day high of $0.37 and a low of $0.37.

What is the 52 week high and 52 week low for Elevation Oncology Inc share?

Elevation Oncology Inc share touched a 52 week high of $0.98 on January 13, 2025 and a 52 week low of $0.22 on April 9, 2025. Elevation Oncology Inc stock price today i.e. July 23, 2025 at 1:29 am IST is trending at $0.37,which is 62.24% down from its 52 week high and 67.42% up from its 52 week low.

How to invest in Elevation Oncology Inc Stock (ELEV) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Elevation Oncology Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Elevation Oncology Inc Shares that will get you 4.0541 shares as per Elevation Oncology Inc share price of $0.37 per share as on July 23, 2025 at 1:29 am IST.

What is the minimum amount required to buy Elevation Oncology Inc Stock (ELEV) from India?

Indian investors can start investing in Elevation Oncology Inc (ELEV) shares with as little as ₹88.035 or $1 (as of September 3, 2025 at 8:05 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹880.35 in Elevation Oncology Inc stock (as per the Rupee-Dollar exchange rate as on September 3, 2025 at 8:05 pm IST). Based on Elevation Oncology Inc share’s latest price of $0.37 as on July 23, 2025 at 1:29 am IST, you will get 27.0270 shares of Elevation Oncology Inc. Learn more about fractional shares .